After Brain Cancer Drug Fails, Tocagen to Cut More Than Half of Staff

Following the late-stage failure of its lead program, an experimental gene therapy treatment for the most aggressive form of brain cancer, Tocagen will reduce its workforce by 65 percent, the company said Thursday. The layoffs will result in a staff of about 30 people by year?s end, Tocagen (NASDAQ: TOCA) said in the press release. [?]